Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
- Forums
- ASX - By Stock
- NEU
- Angelman trial
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.54%
!
$12.92

Angelman trial, page-94
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
Metals & Mining SECTOR NEWS
Global Rights to Transformative Technology for PV Solar Cell Recycling Secured
18 Jun 2025 LITHIUM UNIVERSE LIMITEDLU7 acquires global rights to transformative PV recycling technology from Macquarie University, targeting higher material recoveries from solar waste and backed by $1.7M in investor commitments. The technology... Read more
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
Share
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Share
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
Share
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
Share
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
Share
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
Share
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
Share
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
Share
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
Share
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
Share
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
Share
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Share
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
Share
Question was: Can you please sanity check and provide more detailed and accurate information in the pros and cons. A great researcher responded with the following commentary which called into question some of your assertions and lack of finer important detail.
You are absolutely right to bring in this expert commentary. It provides crucial nuances and corrections to my initial analysis. My previous response, while attempting to be comprehensive, oversimplified some key aspects and made some inaccurate or misleading comparisons. I appreciate the detailed feedback, and I'll revise the Pro/Con list incorporating these points.
Here's the significantly improved and corrected Pro/Con list, addressing the expert's concerns:
1. Ionis Pharmaceuticals (and Biogen): ION582/BIIB121 (ASO)
- Modality: ASO targeting UBE3A-AS.
- Pros:
- Target Specificity: ASOs are designed for high specificity to their target mRNA.
- Potential for Disease Modification: Aims to address the underlying genetic mechanism.
- ASO Platform Experience: While not a guarantee of success, the ASO platform has seen success in other neurological disorders (e.g., Spinraza in SMA). However, this doesn't guarantee success in Angelman Syndrome, and different ASO chemistries exist with varying efficacy and safety profiles.
- Includes Deletions and Mutations: Unlike Ultragenyx's initial focus, Ionis's trial includes patients with both UBE3A gene deletions and mutations (though not all genotypes).
- Includes Ambulatory and Non-Ambulatory: Does not appear to exclude non-ambulatory patients.
- Durable Effect: As stated in the article and clinical trial data, the effect is durable.
- Cons:
- Intrathecal Administration: Requires repeated lumbar punctures, carrying risks of infection, pain, anxiety, and logistical/cost burdens (inpatient/outpatient setting, anesthesia, observation). Frequency is higher during loading, then reduces to 3-4 times per year for maintenance.
- Potential for Off-Target Effects: Risk of unintended mRNA interactions.
- Immune Response: Possible, potentially reducing efficacy or causing inflammation.
- Limited CNS Penetration: Even with intrathecal administration, distribution throughout the brain may be uneven.
- Leg Weakness: A serious side effect, as seen in the HALOS trial.
- Modality: ASO targeting UBE3A-AS.
- Pros:
- Target Specificity: Designed for high specificity to UBE3A-AS.
- Potential for Disease Modification: Addresses the underlying genetic mechanism.
- ASO Platform Experience: (Same caveat as with Ionis – platform experience doesn't guarantee success, and different ASO chemistries exist).
- Optimized Dosing (Ongoing): Actively working to find a dose that balances efficacy and minimizes the risk of lower extremity weakness.
- Durable Effect: Similar to ION582, the effect is durable.
- Cons:
- Intrathecal Administration: Same burdens and risks as Ionis's ASO (repeated lumbar punctures, frequency, logistics, cost).
- Potential for Off-Target Effects: Risk of unintended mRNA interactions.
- Immune Response: Possible.
- Limited CNS Penetration: Potential for uneven distribution in the brain.
- Serious Adverse Events (Lower Extremity Weakness): A significant concern, although dose-dependent and reversible. This has led to trial holds and dose adjustments.
- Initial Trial Exclusions: Initially focused on patients with full deletions of the maternal UBE3A gene (about 70% of AS patients) and excluded non-ambulatory (wheelchair-bound) patients (about 10%). Plans for a broader trial including mutations are underway, but this initial exclusion limits the current data's applicability.
- Modality: Synthetic analog of cGP (a fragment of IGF-1), aiming to enhance synaptic function and reduce neuroinflammation.
- Pros:
- Oral Administration: A major advantage, eliminating the burdens and risks of intrathecal injections.
- Different Mechanism of Action: Could be complementary to ASOs, offering an alternative for those unsuitable for ASO therapy.
- Neuroprotective and Synaptic Enhancement: Aims to address multiple aspects of AS pathophysiology.
- Broad Patient Inclusion: Includes all Angelman syndrome genotypes and does not exclude non-ambulatory patients.
- Positive Phase 2 Data: Demonstrated improvements in various clinical measures.
- Potentially Faster Results: The expert commentary highlights that NNZ-2591 showed effects within 3 months, while ASO trials often report longer-term results. This suggests a potential for quicker onset of benefit.
- Validation from Trofinetide and other indications: Trofinetide's success in Rett Syndrome and NNZ-2591's Phase II data for other conditions adds to validation.
- Cons:
- Not Directly Disease-Modifying (in the same way as ASOs): While it may modify core symptoms, it doesn't directly address the UBE3A gene silencing. However, calling it purely "symptom-addressing" is an oversimplification, as per the expert commentary. It aims to address underlying pathophysiology.
- Less Direct Target (compared to ASOs): The mechanism is broader, which could lead to more variable responses.
- Long-term Efficacy Data is Emerging: While Phase 2 is positive and Phase 3 is ongoing. The expert's point about the potential for increasing benefit over time with NNZ-2591 is important, and long-term data are still being collected for all therapies.
- Disease Modification vs. Symptom Relief: The distinction is not as black-and-white as my initial response suggested. NNZ-2591, while not directly targeting the gene, aims to address the underlying pathophysiology and potentially modify core symptoms. ASOs, while targeting the gene, are not cures and require continuous treatment.
- Long-Term Efficacy: It's inaccurate to say that the long-term efficacy of NNZ-2591 is unknown while implying that ASOs have established long-term efficacy. All therapies are still under investigation, and long-term data are being collected for all of them. The expert makes a valid point about the potential for faster results with NNZ-2591.
- Patient Population: The expert correctly points out the differences in patient inclusion criteria for the trials. Ultragenyx initially focused on a subset of AS patients, while Ionis and Neuren had broader inclusion.
- ASO Platform Validation: While the ASO platform has seen success in other diseases, this is not a guarantee of success in Angelman Syndrome, and different ASO chemistries exist. The success of trofinetide provides validation for NNZ-2591.
- Comparing Efficacy: It is premature to make comparisons.
-
Share
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.92 |
Change
0.070(0.54%) |
Mkt cap ! $1.607B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.85 | $8.049M | 616.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4175 | $12.91 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.03 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4175 | 12.910 |
4 | 4488 | 12.900 |
2 | 1762 | 12.890 |
2 | 3348 | 12.880 |
1 | 1508 | 12.850 |
Price($) | Vol. | No. |
---|---|---|
13.030 | 100 | 1 |
13.040 | 6060 | 2 |
13.050 | 1508 | 1 |
13.060 | 7205 | 8 |
13.080 | 1508 | 1 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CDE
CODEIFAI LIMITED
John Houston / Martin Ross, Executive Chairman / COO
John Houston / Martin Ross
Executive Chairman / COO
Previous Video
Next Video
SPONSORED BY The Market Online